<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: Cyclooxygenase 2 (COX-2) is overexpressed in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and up-regulated by acid or <z:chebi fb="0" ids="3098">bile salt</z:chebi> exposure </plain></SENT>
<SENT sid="1" pm="."><plain>COX-2 inhibition with the selective inhibitor <z:chebi fb="0" ids="8887">rofecoxib</z:chebi> may be important in chemoprevention of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> by decreasing cell proliferation </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Biopsy specimens of esophagus, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, and duodenum were obtained at baseline from 12 patients and were compared with biopsy specimens obtained after 10 days of therapy with <z:chebi fb="0" ids="8887">rofecoxib</z:chebi> 25 mg orally daily </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were maintained asymptomatic on their <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> therapy throughout the study </plain></SENT>
<SENT sid="4" pm="."><plain>COX-2 expression, proliferating cell nuclear antigen (PCNA) expression (proliferation marker), and <z:chebi fb="0" ids="15551">prostaglandin E2</z:chebi> (<z:chebi fb="0" ids="15551">PGE2</z:chebi>) biopsy content (marker of COX activity) were assessed by immunoblotting and enzyme immunoabsorbence assays </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: At baseline, COX-2 expression was 3-fold higher in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> than esophagus and duodenum (P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>After <z:chebi fb="0" ids="8887">rofecoxib</z:chebi> therapy, COX-2 expression in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> decreased by 77% (P &lt; 0.005) </plain></SENT>
<SENT sid="7" pm="."><plain>Similarly at baseline, <z:chebi fb="0" ids="15551">PGE2</z:chebi> content was 2-fold higher in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> than esophagus or duodenum </plain></SENT>
<SENT sid="8" pm="."><plain>After <z:chebi fb="0" ids="8887">rofecoxib</z:chebi> therapy, <z:chebi fb="0" ids="15551">PGE2</z:chebi> content decreased in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> by 59% (P &lt; 0.005) </plain></SENT>
<SENT sid="9" pm="."><plain>At baseline, PCNA expression was also 2-fold higher in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> than squamous esophagus and duodenum (P &lt; 0.005) </plain></SENT>
<SENT sid="10" pm="."><plain>After <z:chebi fb="0" ids="8887">rofecoxib</z:chebi> therapy, PCNA expression in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> decreased by 62.5% (P &lt; 0.005) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="8887">Rofecoxib</z:chebi> 25 mg orally once daily reduces COX-2 expression, <z:chebi fb="0" ids="15551">PGE2</z:chebi> release, and cell proliferation in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Together with acid suppressive therapy, <z:chebi fb="0" ids="8887">rofecoxib</z:chebi> may be a promising chemoprevention agent against <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>